The cannabis industry is riding high on a wave of optimism as the Drug Enforcement Agency (DEA) gears up to reschedule marijuana, downgrading it from a highly dangerous Schedule I drug to a Schedule III substance. This historic move, which comes after a recommendation from the Department of Health and Human Services (HHS), has sparked a surge in pot stocks, with investors anticipating that rescheduling could open up a whole new financial and regulatory frontier in the rapidly evolving cannabis sector.
And let's be real; the numbers speak for themselves. With the global cannabis industry already projected to reach a staggering $64.73 billion in revenue this year, with an anticipated compound annual growth rate (CAGR) of 3.01% from 2024 to 2029, the future looks bright for this niche of the market.
